This company listing is no longer active
Protalix BioTherapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Belangrijke informatie
25.3%
Groei van de winst
54.2%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | -24.5% |
| Inkomstengroei | 10.1% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | -31.3% |
| Laatste winstupdate | 31 Dec 2022 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Protalix BioTherapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Dec 22 | 48 | -15 | 12 | 29 |
| 30 Sep 22 | 48 | -18 | 12 | 31 |
| 30 Jun 22 | 45 | -18 | 12 | 31 |
| 31 Mar 22 | 43 | -24 | 13 | 31 |
| 31 Dec 21 | 38 | -28 | 13 | 30 |
| 30 Sep 21 | 49 | -21 | 12 | 33 |
| 30 Jun 21 | 48 | -21 | 12 | 33 |
| 31 Mar 21 | 53 | -14 | 11 | 35 |
| 31 Dec 20 | 63 | -7 | 11 | 38 |
| 30 Sep 20 | 61 | -7 | 11 | 37 |
| 30 Jun 20 | 65 | -6 | 11 | 39 |
| 31 Mar 20 | 66 | -9 | 11 | 43 |
| 31 Dec 19 | 55 | -18 | 10 | 45 |
| 30 Sep 19 | 47 | -24 | 9 | 45 |
| 30 Jun 19 | 45 | -26 | 11 | 45 |
| 31 Mar 19 | 38 | -26 | 11 | 39 |
| 31 Dec 18 | 34 | -26 | 11 | 33 |
| 30 Sep 18 | 28 | -34 | 13 | 32 |
| 30 Jun 18 | 23 | -40 | 12 | 28 |
| 31 Mar 18 | 25 | -32 | 12 | 30 |
| 31 Dec 17 | 21 | -83 | 12 | 29 |
| 30 Sep 17 | 19 | -73 | 12 | 25 |
| 30 Jun 17 | 16 | -69 | 12 | 23 |
| 31 Mar 17 | 11 | -80 | 11 | 22 |
| 31 Dec 16 | 9 | -29 | 10 | 24 |
| 30 Sep 16 | 7 | -35 | 9 | 24 |
| 30 Jun 16 | 4 | -34 | 9 | 23 |
| 31 Mar 16 | 3 | -29 | 8 | 20 |
Kwaliteitswinsten: PLX is currently unprofitable.
Groeiende winstmarge: PLX is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: PLX is unprofitable, but has reduced losses over the past 5 years at a rate of 25.3% per year.
Versnelling van de groei: Unable to compare PLX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: PLX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-1.1%).
Rendement op eigen vermogen
Hoge ROE: PLX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.